EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pelthos Therapeutics Inc. (PTHS) fair value: what the stock is really worth

We calculate from audited financials what Pelthos Therapeutics Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 18, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US1711262048

PT Pelthos Therapeutics Inc. logo Thin data Jul 18, 2026

Pelthos Therapeutics Inc.

PTHS · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $6.38 · Strongly overvalued (−73%)
!Quality 28/100
!Mixed Growth (revenue 5y +142.6 %/yr)
!Loss-making · -186.2% net margin (TTM)
!negative free cash flow
!Trails peers (2/9)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Pelthos Therapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$48.00 $5.41 Fair Value $6.38 Feb 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.

How to read this chart

31‑month range $5.41 – $48.00 · fair‑value band $4.75 – $9.51 · the $23.52 price screens above the $6.38 fair value. Dashed = 300-day average. As of Jul 18, 2026.

Follow Pelthos Therapeutics in your weekly email

Every Wednesday you see whether Pelthos Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.

Show more

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Stock analysis

Pelthos Therapeutics Inc. (PTHS) currently trades at $23.52, while our model-based Fair Value estimate is $6.38, implying the stock looks roughly 269.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $4.75 (bear) to $9.51 (bull), the price of $23.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Pelthos Therapeutics Inc. reported revenue of $16.8M in FY2025 versus $0 in FY2021. Reported net income was −$43.3M in FY2025.

Key figures

Market cap $101M · P/S ratio 3.64 · EPS (TTM) $−22.92 · Net margin −186% · Return on equity −334% · Return on assets (EBIT) −2,977% · Operating margin −120% · Revenue (TTM) $27.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −73%, PTHS screens richer than that median.

Fair Value models

Bear $4.75 Fair Value $6.38 Bull $9.51
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $5.59 $7.50 $11.19 51
All 1 models by family
Asset-Based
NCAV (Graham) $5.59 $7.50 $11.19 51

Open the full fair value analysis →

Notify me when PTHS reaches fair value

Put PTHS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 28/100

Of which business quality 29 · Market factors (momentum, volatility) 17

Profitability 2
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PTHS screens 269% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pelthos Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −73% · Bottom 25%
Profitability
Return on assets −36% · Bottom 25%
Net margin (TTM) −186% · Bottom 25%
Operating margin (TTM) −120% · Bottom 25%
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.59× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 3.64× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pelthos Therapeutics Inc. · Fair Value
$6.38 −269%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pelthos Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/PTHS

Frequently asked questions

Is Pelthos Therapeutics Inc. (PTHS) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of $6.38 versus a price of $23.52, about −73% upside (overvalued).
What is the fair value of PTHS?
Our model-based fair value for Pelthos Therapeutics Inc. is $6.38 (as of Jul 18, 2026), built from audited fundamentals. The current price: $23.52.
What is the quality score of PTHS?
Pelthos Therapeutics Inc. has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pelthos Therapeutics Inc. (PTHS)?
Our model-based price target is the fair value of $6.38 (as of Jul 18, 2026) from 1 valuation models. Cautious scenario $4.75, optimistic scenario $9.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Pelthos Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $6.38, about −73% upside versus a price of $23.52 (overvalued). Cautious scenario $4.75, optimistic scenario $9.51. The calculation is refreshed regularly with new filings.
What is the revenue of Pelthos Therapeutics Inc. (PTHS)?
Pelthos Therapeutics Inc. reported trailing-twelve-month revenue of about $27.7M (latest available figure, as of Jul 18, 2026).
What is the intrinsic value of Pelthos Therapeutics Inc. (PTHS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pelthos Therapeutics Inc. it is $6.38 per share (as of Jul 18, 2026), against a price of $23.52. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pelthos Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Jul 18, 2026, PTHS trades above its calculated fair value: price $23.52, fair value $6.38, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTHS?
No. The price is what the market pays today ($23.52); the fair value is what the company's own numbers justify ($6.38). For Pelthos Therapeutics Inc. the two are $17.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pelthos Therapeutics Inc. worth?
The market values Pelthos Therapeutics Inc. at about $101M (market capitalisation, as of Jul 18, 2026). Per share that is $23.52; our models calculate a fair value of $6.38 per share.
What do the bullish and bearish scenarios say about PTHS?
Our models span a range for Pelthos Therapeutics Inc.: cautious scenario $4.75, base $6.38, optimistic $9.51 per share (as of Jul 18, 2026, price $23.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pelthos Therapeutics Inc. (PTHS)?
Balance-sheet figures for Pelthos Therapeutics Inc. (as of Jul 18, 2026): return on equity −333.8%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is PTHS from its 52-week high?
Pelthos Therapeutics Inc. trades at $23.52, about 37% below its 52-week high of $37.42 and 29% above the low of $18.19 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $6.38 is for.
Which stocks are comparable to Pelthos Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pelthos Therapeutics Inc. stock attractive at the current price?
The data as of Jul 18, 2026: price $23.52, calculated fair value $6.38 (−73%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTHS calculated?
We run Pelthos Therapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Pelthos Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pelthos Therapeutics Inc. (PTHS)?
The closing price on Sep 23, 2026 was $23.52. Our model-based fair value is $6.38, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pelthos Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($9.51). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($4.75 to $9.51) leaves room in how you read the outcome.

Key figures of Pelthos Therapeutics Inc.

How large is the market capitalisation of Pelthos Therapeutics Inc. (PTHS)?
The market capitalisation of Pelthos Therapeutics Inc. is $101M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pelthos Therapeutics Inc. (PTHS)?
The price-to-sales ratio of Pelthos Therapeutics Inc. is 3.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pelthos Therapeutics Inc. (PTHS)?
Earnings per share at Pelthos Therapeutics Inc. are $−22.92. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pelthos Therapeutics Inc. (PTHS)?
The net margin of Pelthos Therapeutics Inc. is −186% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pelthos Therapeutics Inc. (PTHS)?
The return on equity (ROE) of Pelthos Therapeutics Inc. is −334% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pelthos Therapeutics Inc. (PTHS)?
On an EBIT basis the return on assets of Pelthos Therapeutics Inc. is −2,977% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pelthos Therapeutics Inc. (PTHS)?
The operating margin of Pelthos Therapeutics Inc. is −120% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Pelthos Therapeutics Inc. (PTHS) generate?
The free cash flow of Pelthos Therapeutics Inc. is −$22.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pelthos Therapeutics Inc. (PTHS) carry?
The net debt of Pelthos Therapeutics Inc. is $16.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pelthos Therapeutics Inc. in the live analysis

One click puts Pelthos Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.